Assessing the quality of drug detailing

Journal of Clinical Epidemiology

Volumn 55, Issue 8, 2002, Pages 825-832

  Molloy, William ^a   Strang, David ^b   Guyatt, Gordon ^a   Lexchin, Joel ^c   Bédard, Michel ^a   Dubois, Sacha ^a   Russo, Rosalie ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Drugs; Family doctors; Pharmaceutical detailing; Quality

Indexed keywords

CEFIXIME; CONJUGATED ESTROGEN; LOSARTAN; MISOPROSTOL; RAMIPRIL;

ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG INFORMATION; DRUG QUALITY; HUMAN; MEDICAL EDUCATION; PHARMACOEPIDEMIOLOGY; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; QUALITY CONTROL; QUESTIONNAIRE; VALIDATION PROCESS;

ANALYSIS OF VARIANCE; ATTITUDE OF HEALTH PERSONNEL; CANADA; CHI-SQUARE DISTRIBUTION; DRUG INDUSTRY; DRUG INFORMATION SERVICES; FAMILY PRACTICE; FEMALE; HUMANS; MALE; PHYSICIANS; PRESCRIPTIONS, DRUG; PROFESSIONAL COMPETENCE; QUALITY OF HEALTH CARE;

EID: 0036698232     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-4356(02)00398-0     Document Type: Article

References (35)

1. Caudill T.S., Lurie N., Rich E.C. The influence of pharmaceutical industry advertising on physician prescribing. J Drug Issues. 22(2):1992;331-338.
2. Angus Reid Group Credibility and the marketing mix. 1991;Angus Reid Group; Toronto.
3. Peay M.Y., Peay E.R. Patterns of preference for information sources in the adoption of new drugs by specialists. Soc Sci Med. 31:1990;467-476.
4. Anadaleeb S.S., Tallman R.F. Relationships of physicians with pharmaceutical sales representatives and pharmaceutical companies. an exploratory study Health Mark Q. 13(4):1996;79-89.
5. Lurie N., Rich E.C., Simpson D.E., Meyer J., Schiedermayer D.L., Goodman J.L., McKinney W.P. Pharmaceutical representatives in academic medical centers. interaction with faculty and house staff J Gen Intern Med. 5:1990;240-243.
6. Bower A.D., Burkett G.L. Family physicians and generic drugs. a study of recognition, information sources, prescribing attitudes and practices J Fam Pract. 24:1987;612-616.
7. Peay M.Y., Peay E.R. The role of commercial sources in the adoption of a new drug. Soc Sci Med. 26:1988;1183-1189.
8. Day R. Pharmaceutical company promotion. striking a balance Aust N Z J Med. 28:1998;291-293.
9. Lexchin J. Doctors and detailers. therapeutic education or pharmaceutical promotion? Int J Health Serv. 19:1989;663-679.
10. Roughead E.E., Gilbert A.L., Harvey K.J. Self-regulatory codes of conduct. are they effective in controlling pharmaceutical representatives presentations to general medical practitioners? Int J Health Serv. 28:1998;269-279.
11. Mackowiak J.I., Gagnon J.P. Effects of promotion on pharmaceutical demand. Soc Sci Med. 20:1985;1191-1197.
12. Lexchin J. What information do physicians receive from pharmaceutical representatives? Can Fam Phys. 43:1997;941-945.
13. Sales representatives: a damning report by Prescrire reps monitoring network Prescrire Int. 8:1999;86-89.
14. Strang D.G., Gagnon M., Molloy D.W., Darzins P., Etchells E., Bédard M., Davidson W. Development of a standardized, comprehensive "ideal drug detail" Can J Clin Pharmacol. 8:2001;73-77.
15. Hemminki E. Commercial information on drugs. confusing the physician? J Drug Issues. 18:1988;245-257.
16. Ziegler M.G., Lew P., Singer B.C. The accuracy of drug information from pharmaceutical sales representatives. JAMA. 273(16):1995;1296-1298.
17. McKinney W.P., Schiedermayer D.L., Lurie N., Simpson D.E., Goodman J.L., Rich E.C. Attitudes of internal medicine faculty and residents toward professional interaction with pharmaceutical sales representatives. JAMA. 264:1990;1693-1697.
18. Hayes T.M., Allery L.A., Harding K.G., Owen P.A. Continuing education for general practice and the role of the pharmaceutical industry. Br J Gen Pract. 40:1990;510-512.
19. McKinney W.P., Schiedermayer D.L., Lurie N., Simpson D.E., Goodman J.L., Rich E.C. Attitudes of internal medicine faculty and residents toward professional interactions with pharmaceutical sales representatives. JAMA. 264:1990;1693-1697.
20. Strang D., Molloy W., Bedard M., Darzins P., Etchells E., Davidson W. National survey on the attitudes of Canadian physicians towards drug-detailing by pharmaceutical representatives. Ann RCPSC. 29:1996;474-478.
21. Chan J., Einarson T. Drug detailing in the hospital. background for policy development Can J Hosp Pharm. 44:1991;161-166.
22. Madhavan S., Amonkar M.M., Elliott D., Burke K., Gore P. The gift relationship between pharmaceutical companies and physicians. an exploratory survey of physicians J Clin Pharm Ther. 22:1997;207-215.
23. Blondeel L, Cannoodt L, DeMeyeere M, Proesmans H. Prescription behaviour of 358 Flemish general practitioners. Paper presented at the International Society of General Medicine meeting, Prague; Spring 1987.
24. Greenwood J. Pharmaceutical representatives and the prescribing of drugs by family doctors. PhD Thesis. 1989;Nottingham University; Nottingham, United Kingdom.
25. Bower A.D., Burkett G.L. Family physicians and generic drugs. a study of recognition, information sources, prescribing attitudes, and practices J Fam Pract. 24:1987;612-616.
26. Spingarn R.W., Berlin J.A., Strom B.L. When pharmaceutical manufacturers, employees present grand rounds, what do residents remember? Acad Med. 71:1996;86-88.
27. Caudill T.S., Johnson M.S., Rich E.C., McKinney W.P. Physicians, pharmaceutical sales representatives and the cost of prescribing. Arch Fam Med. 5:1996;201-206.
28. Adlir R.E., Jarjoura D., Phinney M., Poordad F., Gutierrez R., Marnejon T., Greifenstein E., Lappin J., Whittier F.C. Practicing and resident physician views on pharmaceutical companies. J Contin Educ Health Prof. 16:1996;25-32.
29. Roughead E.E., Harvey K.J., Gilbert A.L. Commercial detailing techniques used by pharmaceutical representatives to influence prescribing. Aust N Z J Med. 28(3):1998;306-310.
30. Shaughnessy A.F., Slawson D.C., Bennett J.H. Separating the wheat from the chaff. identifying fallacies in pharmaceutical promotion J Gen Intern Med. 9:1994;563-568.
31. Molloy D.W., Smith S.D., Jubelius R.M. The Ideal Detail Program - comprehensive, up-to-date drug detailing. Health Law Can. 19:1999;89-95.
32. Molloy D.W., Strang D.G., Wadhwa S.G., Carter P.C. The fine detail. 1997;Newgrange Press; Troy.
33. Guyatt G., Rennie D. The users' guides to the medical literature. a manual for evidence-based clinical practice:2002;Chicago; AMA Press.
34. Guyatt G.H., Feeny D.H., Patrick D.L. Measuring health-related quality of life. Ann Intern Med. 118:1993;622-629.
35. Representatives S. Review). Prescrire International. 8:1999;86-89. 36. Editorial. Getting good value from drug reps. Drug Ther Bull 1983;21:13-5.